NASDAQInformation TechnologyComputer HardwareSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for QCLS yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Improve operating income toward break-even | A primary condition in Q/C TECHNOLOGIES INC's published investment case. The stated target is operating loss improves to better than -$1.86M next 4 quarters. | Under Pressure | operating loss worsens beyond -$1.86M next 4 quarters | Operating income: $-6.791M FY2026-Q2; GAAP. Published target: operating loss improves to better than -$1.86M next 4 quarters. Target period is not explicitly aligned with this observation. Aug 12, 2026-6,790,736 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making technology development story, not a proven compounder. The long-term thesis is in a watch state, with medium confidence and weak recent financial performance.
The valuation evidence says QCLS is cheap versus peers, but the model has low confidence and the expectations gap is slightly negative. The priced-in tag is justified, and no fragility gates fired, so the evidence does not point to unusually concentrated fragility in what the market assumes.
Near term, earnings risk is elevated, with a 67% estimated chance of a miss next quarter, and recent performance has been weak relative to its industry cohort. Over the multi-year view, operating losses and cash burn have worsened despite management repeatedly naming them as priorities; integrated photonics is still early-stage, with no revenue or margin data to show progress.
The favorable case depends on the Fed beginning rate cuts or major technology peers stabilizing, which could improve the sector backdrop. The unfavorable case is materially slower GDP growth, while QCLS’s own execution on reducing losses and cash burn remains a central test.
Over the next 1 to 3 years, the thesis depends on measurable progress in loss reduction and cash use, alongside evidence that the new photonics program can advance beyond early development. Current evidence is weak, and the low-confidence valuation view leaves meaningful uncertainty. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Reduce negative cash from operations | A primary condition in Q/C TECHNOLOGIES INC's published investment case. The stated target is reduce cash burn to better than -$3.29M next 4 quarters. | Broken | cash burn worsens beyond -$3.29M next 4 quarters | Cash from operations: $-1.819M FY2026-Q2; GAAP. Published target: reduce cash burn to better than -$3.29M next 4 quarters. Target period is not explicitly aligned with this observation. Jun 30, 2026-1,818,533 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Manage M&A and technology licensing agreements | A supporting condition in Q/C TECHNOLOGIES INC's published investment case. The stated target is maintain active management of material agreements ongoing. | Under Pressure | no active management or new material agreements for 2 quarters | 2 material agreements terminated vs target of active management Company terminated LightSolver Technology License and Chelsea Voss Consulting Agreement in 2026, signaling a lapse in active M&A/licensing management. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Reduce net losses toward break-even | A primary condition in Q/C TECHNOLOGIES INC's published investment case. The stated target is net loss improves to better than -$1.24M next 4 quarters. | Under Pressure | net loss worsens beyond -$1.24M next 4 quarters | Net income: $-6.616M FY2026-Q2; GAAP. Published target: net loss improves to better than -$1.24M next 4 quarters. Target period is not explicitly aligned with this observation. Aug 12, 2026-6,616,236 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Nov 18, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.